Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.58 |
| ▸ | FNTB | P49356 | 14/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.58 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462521 | 0.88 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL15124470 | 0.87 | FNTA (0.59) | FNTAFNTBPGGT1B | |
| SCHEMBL15124855 | 0.78 | FNTA (0.46) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL461093 | 0.77 | FNTA (0.50) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL15124696 | 0.74 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL15124423 | 0.72 | FNTA (0.44) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL31534292 | 0.71 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL463380 | 0.71 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL15124860 | 0.65 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL29184192 | 0.65 | HSD11B1 (0.53) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034038-A2 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | FNTA 1/4885FNTB 2/4885PGGT1B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.